Danaher Co. (NYSE:DHR) Shares Sold by Traynor Capital Management Inc.

Traynor Capital Management Inc. lowered its position in Danaher Co. (NYSE:DHR) by 15.2% during the 4th quarter, Holdings Channel.com reports. The firm owned 10,847 shares of the conglomerate’s stock after selling 1,945 shares during the quarter. Traynor Capital Management Inc.’s holdings in Danaher were worth $2,509,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently made changes to their positions in DHR. Apella Capital LLC boosted its holdings in shares of Danaher by 2.0% in the third quarter. Apella Capital LLC now owns 2,332 shares of the conglomerate’s stock valued at $579,000 after acquiring an additional 46 shares in the last quarter. Nations Financial Group Inc. IA ADV boosted its holdings in shares of Danaher by 0.8% in the first quarter. Nations Financial Group Inc. IA ADV now owns 6,064 shares of the conglomerate’s stock valued at $1,779,000 after acquiring an additional 46 shares in the last quarter. Peddock Capital Advisors LLC boosted its holdings in shares of Danaher by 0.9% in the third quarter. Peddock Capital Advisors LLC now owns 5,523 shares of the conglomerate’s stock valued at $1,370,000 after acquiring an additional 47 shares in the last quarter. IMS Capital Management boosted its holdings in Danaher by 0.4% during the second quarter. IMS Capital Management now owns 11,046 shares of the conglomerate’s stock worth $2,651,000 after buying an additional 49 shares in the last quarter. Finally, New Hampshire Trust boosted its holdings in Danaher by 0.3% during the third quarter. New Hampshire Trust now owns 14,438 shares of the conglomerate’s stock worth $3,582,000 after buying an additional 50 shares in the last quarter. Institutional investors and hedge funds own 79.05% of the company’s stock.

Insider Activity at Danaher

In other Danaher news, SVP Daniel Raskas sold 23,757 shares of the business’s stock in a transaction on Monday, February 26th. The shares were sold at an average price of $252.00, for a total transaction of $5,986,764.00. Following the completion of the transaction, the senior vice president now owns 38,102 shares of the company’s stock, valued at approximately $9,601,704. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other Danaher news, SVP Daniel Raskas sold 23,757 shares of the business’s stock in a transaction on Monday, February 26th. The shares were sold at an average price of $252.00, for a total transaction of $5,986,764.00. Following the completion of the transaction, the senior vice president now owns 38,102 shares of the company’s stock, valued at approximately $9,601,704. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, SVP Georgeann Couchara sold 2,622 shares of the business’s stock in a transaction dated Tuesday, February 13th. The stock was sold at an average price of $242.67, for a total transaction of $636,280.74. Following the transaction, the senior vice president now owns 4,244 shares in the company, valued at approximately $1,029,891.48. The disclosure for this sale can be found here. In the last 90 days, insiders sold 32,957 shares of company stock valued at $8,265,802. Insiders own 11.10% of the company’s stock.

Danaher Trading Up 0.4 %

NYSE DHR traded up $0.95 on Thursday, hitting $249.72. 2,434,047 shares of the stock were exchanged, compared to its average volume of 2,765,013. The company’s 50-day moving average price is $247.17 and its two-hundred day moving average price is $230.53. The company has a market capitalization of $184.72 billion, a price-to-earnings ratio of 39.08, a P/E/G ratio of 3.77 and a beta of 0.84. Danaher Co. has a 52-week low of $182.09 and a 52-week high of $259.00. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.68 and a quick ratio of 1.37.

Danaher (NYSE:DHR) last issued its earnings results on Tuesday, January 30th. The conglomerate reported $2.09 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.91 by $0.18. The company had revenue of $6.41 billion during the quarter, compared to analyst estimates of $6.10 billion. Danaher had a net margin of 17.26% and a return on equity of 12.25%. The company’s revenue for the quarter was down 10.2% on a year-over-year basis. During the same quarter last year, the business posted $2.87 EPS. Research analysts predict that Danaher Co. will post 7.63 EPS for the current year.

Danaher Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, April 26th. Investors of record on Thursday, March 28th will be paid a $0.27 dividend. This represents a $1.08 annualized dividend and a dividend yield of 0.43%. The ex-dividend date of this dividend is Wednesday, March 27th. This is a positive change from Danaher’s previous quarterly dividend of $0.24. Danaher’s payout ratio is presently 15.02%.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on DHR. KeyCorp raised their target price on shares of Danaher from $260.00 to $290.00 and gave the stock an “overweight” rating in a report on Thursday, February 1st. StockNews.com cut shares of Danaher from a “buy” rating to a “hold” rating in a report on Wednesday, January 31st. Citigroup raised their target price on shares of Danaher from $255.00 to $280.00 and gave the stock a “buy” rating in a report on Wednesday, January 31st. TheStreet upgraded shares of Danaher from a “c+” rating to a “b-” rating in a report on Friday, December 8th. Finally, Raymond James raised their target price on shares of Danaher from $240.00 to $270.00 and gave the stock an “outperform” rating in a report on Wednesday, January 31st. Seven equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $266.00.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.